Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Saxagliptin - AstraZeneca

Drug Profile

Saxagliptin - AstraZeneca

Alternative Names: BMS-477118; Onglyza; OPC-262

Latest Information Update: 11 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer AstraZeneca; Bristol-Myers Squibb; Otsuka Pharmaceutical
  • Class Adamantanes; Antihyperglycaemics; Azabicyclo compounds; Dipeptides; Nitriles; Organic bridged compounds; Piperidines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 22 Aug 2019 Bristol-Myers Squibb completes a phase III trial for Type-2 diabetes mellitus (Combination therapy) in United Kingdom, USA, Sweden, Poland, Mexico, Hungary, Czech Republic, Romania, Russia and Germany (NCT02419612)
  • 24 Jun 2018 Biomarkers information updated
  • 09 Nov 2017 Bristol-Myers Squibb and AstraZeneca completes a phase III trial for Type-2 diabetes mellitus (Combination therapy) in USA, Czech Republic, Denmark, Germany, Hungary, Mexico, Poland, Romania, South Africa, Spain and Sweden (PO) (NCT02551874)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top